Conference ReviewProgress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
Introduction
The Seventh Eilat Conference on New Antiepileptic Drugs (AEDs) (EILAT VII) took place in Villasimius, Sardinia, Italy from the 9th to 13th May 2004. Basic scientists, clinical pharmacologists and neurologists from 24 countries attended the conference, whose main themes included advances in pathophysiology of drug resistance, new AEDs in pediatric epilepsy syndromes, modes of AED action and spectrum of adverse effects and a re-appraisal of comparative responses to AED combinations. Consistent with previous formats of this conference, the central part of the conference was devoted to a review of AEDs in development, as well as updates on second-generation AEDs. This article summarizes the information presented on drugs in development, including atipamezole (AMZ), BIA-2-093, fluorofelbamate (FFBM), NPS 1776, pregabalin (PGB), retigabine (RGB), safinamide (SAF), SPM 927, stiripentol (STP), talampanel (TLP), ucb 34714 and valrocemide (TV 1901, VLR). Updates on felbamate (FBM), gabapentin (GBT), lamotrigine (LTG), levetiracetam (LEV), oxcarbazepine (OXC), tiagabine (TGB), topiramate (TPM), vigabatrin (VGB), zonisamide (ZNS), new oral and parenteral formulations of valproic acid (VPA) and SPM 927 and the antiepileptic vagal stimulator device were also presented.
Section snippets
Atipamezole
A. Pitkänena,b, J. Nissinena, A. Haapalinnac, J. Sirviöc
aA.I. Virtanen Institute for Molecular Sciences, University of Kuopio, Kuopio, Finland
bKuopio University Hospital, Department of Neurology, Kuopio, Finland
cOrion Corporation, Orion Pharma, Turku, Finland
Felbamate
B. A. Roeckleina, J. Gatesb, D. Dickensb
aMedPointe Pharmaceuticals, Somerset, NJ, USA
bMinnesota Epilepsy Group, PA, Minneapolis, Minnesota, USA
Pharmacokinetics and clinical experience with divalproex-ER
J.C. Cloyd, R.C. Reed, S. Dutta, T.B. Smith
aCollege of Pharmacy, University of Minnesota, Minneapolis, MN, USA
bAbbott Laboratories, Global Pharmaceutical Research & Development, Abbott Park, IL 60064, USA
Vagus nerve stimulation
S. C. Schachter
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA
References (231)
- et al.
Long-term effects of 24-month treatment with vagus nerve stimulation on behaviour in children with Lennox-Gastaut syndrome
Epilepsy Behav.
(2002) - et al.
Levetiracetam monotherapy for newly diagnosed epilepsy patients
Seizure
(2003) - et al.
Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024
Eur. J. Pharmacol.
(2000) - et al.
Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels
Biochem. Pharmacol.
(2001) - et al.
Alpha2-adrenoceptors modulate kainic acid-induced limbic seizures
Eur. J. Pharmacol.
(1985) - et al.
Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode
J. Affect. Disord.
(2004) - et al.
Evidence for sustained efficacy of Levetiracetam as add-on epilepsy therapy
Epilepsy Res.
(2003) - et al.
Clinical experience of marketed levetiracetam in an epilepsy clinic—a one-year follow up study
Seizure
(2003) - et al.
Progress report on new antiepileptic drugs: a summary of the Fourth Eilat Conference (EILAT IV)
Epilepsy Res.
(1999) - et al.
Progress report on new antiepileptic drugs: a summary of the Fourth Eilat Conference (EILAT V)
Epilepsy Res.
(2001)
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference EILAT VI
Epilepsy Res.
The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain
Eur. J. Pharmacol.
Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1
Eur. J. Pharmacol.
Glutamate receptor antagonists differentially affect the protective activity of conventional antiepileptics against amygdala-kindled seizures in rats
Eur. Neuropsychopharmacol.
Rationale and evidence for use of oxcarbazepine in neuropathic pain
J. Pain Symptom. Manage.
A review of functional neuroimaging studies of vagus nerve stimulation (VNS)
J. Psychiatr. Res.
Long-term outcome of vagus nerve stimulation for refractory partial epilepsy
Epilepsy Behav.
Stiripentol in severe myoclonic epilepsy in infancy: a randomized placebo-controlled syndrome-dedicated trial
Lancet
Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy
Epilepsy Res.
Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam
Epilepsy Behav.
LY 300164 a novel antagonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs
Eur. J. Pharmacol.
Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers
Epilepsy Res.
Divalproex-ER pharmacokinetics in older children and adolescents
Pediatr. Neurol.
Acute behavioural and EEG effects of NW-1015 on electrically induced afterdischarge in conscious monkeys
Epilepsy Res.
Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C
Pain
Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex
Neuropharmacology
The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats
Eur. J. Pharmacol.
Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model
Reprod. Toxicol.
Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig
Pain
Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability
Epilepsy Res.
Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials
Epilepsy Res.
α2-Adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions and neuronal damage
Brain Res.
Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(−)-10,11-dihydro-10-hydroxy carbamazepine
Epilepsy Res.
Two new actions of topiramate: inhibition of depolarizing GABAA-mediated responses and activation of a potassium conductance
Neuropharmacology
Symptomatic hyponatremia in patients on oxcarbazepine therapy for the treatment of neuropathic pain: two case reports
J. Pain Palliat. Care Pharmacother.
Pharmacokinetic profile of BIA 2-093, a putative new antiepileptic drug, after single and multiple administration in human healthy volunteers
Epilepsia
Safety, tolerability and pharmacokineticc profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans
Drugs RD
Vagus nerve stimulation therapy for patients with persistent seizures after epilepsy surgery
Stereotact. Funct. Neurosurg.
Long-term pregabalin treatment protects basal cortices and delays the occurrence of spontaneous seizures in the lithium-pilocarpine model in the rat
Epilepsia
Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level
J. Neurochem.
Topiramate: effective as monotherapy in dose–response study in newly diagnosed epilepsy
Epilepsia
Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose–response study in adults with partial seizures
Epilepsia
Investigation into the mechanisms of vagus nerve stimulation for intractable epilepsy, using 99mTc-HMPAO SPET brain images
Eur. J. Nucl. Med. Mol. Imag.
Anticonvulsant and sodium channel-blocking properties of novel 10,11- dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives
J. Med. Chem.
Sustained efficacy and long-term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial seizures
Epilepsia
Pharmacokinetic interactions of topiramate
Clin. Pharmacokinet.
Short communication: human cytochrome P450 maximal activities in pediatric versus adult liver
Drug Metab. Dispos.
Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine
Epilepsia
Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures
Neurology
Cited by (198)
Polypharmacology: The science of multi-targeting molecules
2022, Pharmacological ResearchDual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)
2022, European Journal of Medicinal ChemistrySafinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies
2021, Brain Research BulletinCitation Excerpt :Nevertheless, eight patients reported possible or probable adverse events related to safinamide treatment, which were mild to moderate and were mainly dizziness, vertigo, headache and blurred vision. Although the study had inadequate power to assess efficacy, 41 % patient had > 50 % decrease in frequency of seizures after starting safinamide therapy compared to baseline (Bialer et al., 2004). This study showed positive results in efficacy as well as tolerability of safinamide.